# Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention

> **NCT05241431** · PHASE2,PHASE3 · UNKNOWN · sponsor: **University of Aarhus** · enrollment: 106 (estimated)

## Conditions studied

- Aortic Stenosis
- Left Ventricle Hypertrophied

## Interventions

- **DRUG:** SGLT2 inhibitor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05241431
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-12
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2022-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05241431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05241431, "Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT05241431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*